JP2020532535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532535A5 JP2020532535A5 JP2020512443A JP2020512443A JP2020532535A5 JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5 JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020512443 A JP2020512443 A JP 2020512443A JP 2020532535 A5 JP2020532535 A5 JP 2020532535A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- sepiapterin
- composition according
- crystal
- tetrahydrobiopterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 43
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 claims 35
- 229940126478 sepiapterin Drugs 0.000 claims 35
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 claims 34
- 239000013078 crystal Substances 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 claims 10
- 229960004617 sapropterin Drugs 0.000 claims 10
- 230000036470 plasma concentration Effects 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 239000003963 antioxidant agent Substances 0.000 claims 4
- 230000003078 antioxidant effect Effects 0.000 claims 4
- 235000006708 antioxidants Nutrition 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
- 239000002270 dispersing agent Substances 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000011252 Phenylketonuria Diseases 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims 2
- 229940077388 benzenesulfonate Drugs 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 229960005168 croscarmellose Drugs 0.000 claims 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- VZPVHFFRKWFPLX-UHFFFAOYSA-N 2-hydroxy-N-(4-oxo-3H-pteridin-2-yl)propanamide Chemical compound CC(O)C(=O)Nc1nc2nccnc2c(=O)[nH]1 VZPVHFFRKWFPLX-UHFFFAOYSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 claims 1
- 102100031226 Alkylglycerol monooxygenase Human genes 0.000 claims 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 claims 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 claims 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 claims 1
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 claims 1
- 206010069116 Tetrahydrobiopterin deficiency Diseases 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 235000003969 glutathione Nutrition 0.000 claims 1
- 108010043705 glyceryl-ether monooxygenase Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 235000020944 retinol Nutrition 0.000 claims 1
- 229960003471 retinol Drugs 0.000 claims 1
- 239000011607 retinol Substances 0.000 claims 1
- -1 sepiapterin gentisate salt Chemical class 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000008247 solid mixture Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023088749A JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553603P | 2017-09-01 | 2017-09-01 | |
| US62/553,603 | 2017-09-01 | ||
| US201862678069P | 2018-05-30 | 2018-05-30 | |
| US62/678,069 | 2018-05-30 | ||
| PCT/US2018/049359 WO2019046849A1 (en) | 2017-09-01 | 2018-09-04 | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Division JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532535A JP2020532535A (ja) | 2020-11-12 |
| JP2020532535A5 true JP2020532535A5 (enExample) | 2021-10-14 |
Family
ID=65526057
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512443A Pending JP2020532535A (ja) | 2017-09-01 | 2018-09-04 | セピアプテリンを含む医薬組成物及びその使用 |
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023088749A Pending JP2023116556A (ja) | 2017-09-01 | 2023-05-30 | セピアプテリンを含む医薬組成物及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11752154B2 (enExample) |
| EP (1) | EP3675863A4 (enExample) |
| JP (2) | JP2020532535A (enExample) |
| CN (1) | CN111491635A (enExample) |
| BR (1) | BR112020003865A8 (enExample) |
| CA (1) | CA3073957A1 (enExample) |
| MX (1) | MX2020002271A (enExample) |
| WO (1) | WO2019046849A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) * | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
| AU2021209935A1 (en) | 2020-01-24 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating Parkinson's disease with sepiapterin |
| US20230077104A1 (en) * | 2020-02-19 | 2023-03-09 | The United States Government As Represented By The Department Of Veteran Affairs | L-sepiapterin and methods of use for treating diseases and disorders |
| WO2022173823A1 (en) | 2021-02-09 | 2022-08-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| JP2024506336A (ja) | 2021-02-09 | 2024-02-13 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | 膠芽腫の治療方法 |
| WO2023055923A1 (en) | 2021-09-29 | 2023-04-06 | Ptc Therapeutics, Inc. | Pharmaceutical composition of sepiapterin |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| ES2177654T3 (es) | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| EP0854934A4 (en) | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
| US8188043B2 (en) * | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| WO2005041975A1 (en) | 2003-10-31 | 2005-05-12 | Altana Pharma Ag | Use of bh4 for the treatment of respiratory diseases |
| JP2007536210A (ja) | 2003-11-17 | 2007-12-13 | メルック・エプロバ・アクチエンゲゼルシヤフト | （６ｒ）−ｌ−エリスロ−テトラヒドロビオプテリンジヒドロクロライドの結晶形 |
| HUE029533T2 (en) | 2003-11-17 | 2017-03-28 | Biomarin Pharm Inc | Treatment of phenylketonuria with BH4 |
| AU2004290692A1 (en) | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| EP2436379A1 (en) * | 2004-11-17 | 2012-04-04 | BioMarin Pharmaceutical Inc. | Stable tablet formulation |
| EP1819340A2 (en) | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| WO2006118322A1 (en) | 2005-04-28 | 2006-11-09 | Shiratori Pharmaceutical Co., Ltd. | Method for producing hydrazone derivatives |
| US20080075666A1 (en) * | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| DK3461503T3 (da) | 2007-04-11 | 2022-02-14 | Biomarin Pharm Inc | Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder |
| NZ588379A (en) | 2008-03-10 | 2012-07-27 | Takeda Pharmaceutical | Crystal of benzimidazole compound |
| ES2736730T3 (es) * | 2008-08-12 | 2020-01-07 | Orpha Swiss Gmbh | Forma de administración farmacéutica que contiene tetrahidrobiopterina |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| MX2012002179A (es) | 2009-08-20 | 2012-03-16 | Novartis Ag | Compuestos heterociclicos de oxima. |
| US20130197000A1 (en) | 2010-04-22 | 2013-08-01 | Nihon University | Drug and food/drink for preventing or improving cerebral dysfunction |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP2680848A4 (en) | 2011-03-01 | 2014-11-05 | Rubicon Res Private Ltd | STABLE TETRAHYDROBIOPTERINE COMPOSITIONS |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) * | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| EP2926805B1 (en) * | 2014-03-31 | 2016-05-18 | Vasopharm GmbH | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions |
| AU2017286544B2 (en) | 2016-06-13 | 2022-10-20 | Meharry Medical College | Modulation of the nitric oxide synthase pathway for oral health |
| JP2019527242A (ja) * | 2016-07-29 | 2019-09-26 | ディファーマ エッセ．ア． | サプロプテリンジヒドロクロリドを含む医薬組成物キット |
| WO2018102314A1 (en) | 2016-11-29 | 2018-06-07 | Censa Pharmaceuticals Inc. | Polymorphic form of sepiapterin |
| IL266955B2 (en) | 2016-11-29 | 2023-09-01 | Ptc Therapeutics Mp Inc | Polymorphs of spiafatrin and its salts |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
| CA3102070A1 (en) | 2018-05-30 | 2019-12-05 | Ptc Therapeutics Mp, Inc. | Pharmaceutically acceptable salts of sepiapterin |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| EP3801534A4 (en) | 2018-05-30 | 2022-03-16 | PTC Therapeutics MP, Inc. | COMPOSITIONS AND METHODS TO INCREASE TETRAHYDROBIOPTERIN PLASMA EXPOSURE |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| KR20220070477A (ko) | 2019-09-25 | 2022-05-31 | 피티씨 테라퓨틱스 엠피, 인크. | 고페닐알라닌혈증 치료 방법 |
-
2018
- 2018-09-04 WO PCT/US2018/049359 patent/WO2019046849A1/en not_active Ceased
- 2018-09-04 BR BR112020003865A patent/BR112020003865A8/pt active Search and Examination
- 2018-09-04 MX MX2020002271A patent/MX2020002271A/es unknown
- 2018-09-04 CN CN201880070952.7A patent/CN111491635A/zh active Pending
- 2018-09-04 JP JP2020512443A patent/JP2020532535A/ja active Pending
- 2018-09-04 CA CA3073957A patent/CA3073957A1/en active Pending
- 2018-09-04 EP EP18850633.1A patent/EP3675863A4/en active Pending
-
2019
- 2019-10-31 US US16/670,362 patent/US11752154B2/en active Active
-
2023
- 2023-05-30 JP JP2023088749A patent/JP2023116556A/ja active Pending
- 2023-08-18 US US18/235,486 patent/US12213982B2/en active Active
-
2024
- 2024-12-20 US US18/990,477 patent/US20250195526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532535A5 (enExample) | ||
| HRP20230931T1 (hr) | Kristalični oblici n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)kinolin-8-sulfonamida | |
| ES2947819T3 (es) | Método para el tratamiento del cáncer con N-((4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenil]-3-carboxamida | |
| JP2021505575A5 (enExample) | ||
| JP2021504338A5 (enExample) | ||
| AU2012274160B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| CA2854836C (en) | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | |
| JP2009506014A5 (enExample) | ||
| BR112012003592B1 (pt) | composição farmacêutica contendo derivado de quinolina | |
| JP2015511621A5 (enExample) | ||
| JP2017537899A5 (enExample) | ||
| EA032421B1 (ru) | Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| JP2018168191A5 (enExample) | ||
| HRP20180018T1 (hr) | Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja | |
| JP2016503010A5 (enExample) | ||
| JP2016006070A (ja) | Ｈｄａｃ阻害剤と代謝拮抗剤の組み合わせ | |
| JP2008528542A5 (enExample) | ||
| JPWO2009038112A1 (ja) | Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤 | |
| JP2019516684A5 (enExample) | ||
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| RU2015140611A (ru) | Коньюгат бензофуранона и индола или азаиндола, его получение и применения | |
| JP2011530540A5 (enExample) | ||
| CN106551946B (zh) | 一种含三氟胸苷和盐酸替比嘧啶的药物组合物及制备方法 | |
| JP2015534573A5 (enExample) | ||
| KR20210060515A (ko) | 전립선 암의 치료를 위한 병용 요법 |